Previous close | 171.06 |
Open | 169.33 |
Bid | 165.66 x 900 |
Ask | 165.74 x 3100 |
Day's range | 165.10 - 170.39 |
52-week range | 115.03 - 217.25 |
Volume | |
Avg. volume | 4,976,447 |
Market cap | 63.618B |
Beta (5Y monthly) | 1.69 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.96 |
Earnings date | 22 Feb 2023 - 27 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 207.29 |
Moderna (MRNA) closed the most recent trading day at $171.06, moving +0.46% from the previous trading session.
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.
In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.